Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Which Brilliant Home Gadget Can't You Reside Without? - 2Russian billionaire says 12-hour days and 6-day workweeks could help save the economy
- 3Lawsuit claims ChatGPT exacerbated man's delusions leading to murder-suicide
- 4Whale stranded off Germany for days found stuck again
- 5Unsold Rams May Be Less expensive Than You Suspect
- UB professor shares his experience on almost becoming an astronaut
- Getting Your Youngsters' Future: Grasping Legacy Regulations
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Sound Maturing: Wellbeing Tips for Each Life Stage
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- Kate Hudson, 46, says she doesn't need long workouts to feel good
- The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World
- Well known SUVs With Low Energy Utilization In 2024
- The Significance of Health Projects in Senior Protection.
